Boston-based AI Proteins is a biotech company on a mission to re-imagine protein therapeutics with a novel approach for designing entirely new proteins. Using AI-enabled design and a high-throughput drug discovery platform, AI Proteins creates de novo miniproteins optimized for a variety of therapeutic applications. Partnered with leading biopharmaceutical companies, AI Proteins continues to pursue collaborations across a wide variety of therapeutic areas in addition to advancing its internal pipeline. The AI Proteins platform can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/19/25 | $41,500,000 | Series A |
Cobro Ventures Lightchain Capital Mission BioCapital  Sante Ventures | undisclosed |
